Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442402 · ClinicalTrials.gov registry record
APOL1 Gene Variants in African American Kidney Transplant Recipients
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 39
- Enrollment target
NCT01442402 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 39 participants.
The verdict
NCT01442402 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an African American kidney transplant recipient and the risk of recurrent disease Aim 3: Investigate mechanisms of APOL1 associated kidney disease by prospectively following African American kidney transplant recipients throughout their clinical course.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442402
The ClinicalTrials.gov registry entry for NCT01442402 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01442402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442402 about?
NCT01442402 is a clinical study titled "APOL1 Gene Variants in African American Kidney Transplant Recipients". Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an African American kidney transplant recipient and the risk of recurrent...
What is the current status of trial NCT01442402?
This trial is currently terminated. The enrollment target is 39 participants. The study started on 2014-04. Estimated completion is 2014-04.
Who is sponsoring clinical trial NCT01442402?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.